Pay in 4 interest-free payments of $5.79 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Novo Nordisk said the outlook for its International Operations business reflects continued volume penetration from GLP-1 treatments and market expansion, mainly within obesity, as well as intensifying competition and negative impacts from the compound patent expiry of the semaglutide molecule in certain markets. International Operations sales increased 6% at constant exchange rates during the first quarter, driven by growth in Europe and Asia-Pacific markets, although the company said the performance was partly offset by weakness in emerging markets and China
The data do not include information on the number of days supplied in each prescription
Each works differently
Zepbound doesn't affect fluid balance
US$ 27.21
US$ 22.79
US$ 26.95
US$ 29.11
US$ 27.35
US$ 21.04
